chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Sore arm; Sweaty; Headache, less severe; Fever, less severe; Had a full third dose of the Moderna vaccine and they are not immunocompromised; Had a full third dose of the Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), HYPERHIDROSIS (Sweaty), HEADACHE (Headache, less severe), PYREXIA (Fever, less severe) and EXTRA DOSE ADMINISTERED (Had a full third dose of the Moderna vaccine and they are not immunocompromised) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Aug-2021, the patient experienced EXTRA DOSE ADMINISTERED (Had a full third dose of the Moderna vaccine and they are not immunocompromised). 24-Aug-2021, the patient experienced INCORRECT DOSE ADMINISTERED (Had a full third dose of the Moderna vaccine). On 25-Aug-2021, the patient experienced PAIN IN EXTREMITY (Sore arm), HYPERHIDROSIS (Sweaty), HEADACHE (Headache, less severe) and PYREXIA (Fever, less severe). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) on 25-Aug-2021 for Adverse event, at an unspecified dose and frequency. On 26-Aug-2021, PAIN IN EXTREMITY (Sore arm), HYPERHIDROSIS (Sweaty), HEADACHE (Headache, less severe) and PYREXIA (Fever, less severe) had resolved. At the time of the report, EXTRA DOSE ADMINISTERED (Had a full third dose of the Moderna vaccine and they are not immunocompromised) and INCORRECT DOSE ADMINISTERED (Had a full third dose of the Moderna vaccine) outcome was unknown.            The consumer stated that he had a full third dose of the Moderna vaccine and he was not immunocompromised. The consumer stated that the onset of symptoms was the day after getting the shot and lasted for a day after the third dose.  The consumer stated that he took Advil as a treatment medication after the first 24 hours.  No concomitant product use was provided by the reporter.   This case was linked to MOD-2021-309106 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Pain in extremity
Clinical narrative: the pain localization varies in the arm (after second dose); pain from the shoulder all the way down into the hand (after second dose); Tired for a week (after first dose); This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (the pain localization varies in the arm (after second dose)), FATIGUE (Tired for a week (after first dose)) and ARTHRALGIA (pain from the shoulder all the way down into the hand (after second dose)) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No medical history provided.  Concomitant products included DULOXETINE HYDROCHLORIDE, LISINOPRIL DIHYDRATE (LISINOPRIL [LISINOPRIL DIHYDRATE]), AMLODIPINE BESILATE, OMEPRAZOLE SODIUM (OMEPRAZOLE [OMEPRAZOLE SODIUM]), FAMOTIDINE (FAMOTIDINE ACID REDUCER), HYDROXYZINE HYDROCHLORIDE (HYDROXYZINE [HYDROXYZINE HYDROCHLORIDE]), METOPROLOL SUCCINATE, GABAPENTIN, MONTELUKAST, ALPRAZOLAM (XANAX SR), VITAMIN C [ASCORBIC ACID] and CALCIUM for an unknown indication.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Mar-2021, the patient experienced FATIGUE (Tired for a week (after first dose)). On an unknown date, the patient experienced PAIN IN EXTREMITY (the pain localization varies in the arm (after second dose)) and ARTHRALGIA (pain from the shoulder all the way down into the hand (after second dose)). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (the pain localization varies in the arm (after second dose)) and ARTHRALGIA (pain from the shoulder all the way down into the hand (after second dose)) outcome was unknown and FATIGUE (Tired for a week (after first dose)) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication butrotion-HclXl tab 300mg 1/night is used.   This case was linked to MOD-2021-314900.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Inflammation, Pain in extremity, Rash
Clinical narrative: shooting pain from shoulder down to hand; rash is inflamed; shooting pain from shoulder down to hand; developed a rash on her left arm extending from arm to elbow and upto shoulder; This spontaneous case was reported by a pharmacist and describes the occurrence of PAIN IN EXTREMITY (shooting pain from shoulder down to hand), INFLAMMATION (rash is inflamed), RASH (developed a rash on her left arm extending from arm to elbow and upto shoulder) and ARTHRALGIA (shooting pain from shoulder down to hand) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Aug-2021, the patient experienced RASH (developed a rash on her left arm extending from arm to elbow and upto shoulder). On an unknown date, the patient experienced PAIN IN EXTREMITY (shooting pain from shoulder down to hand), INFLAMMATION (rash is inflamed) and ARTHRALGIA (shooting pain from shoulder down to hand). The patient was treated with SULFAMETHOXAZOLE, TRIMETHOPRIM (BACTRIM DS) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (shooting pain from shoulder down to hand), INFLAMMATION (rash is inflamed) and ARTHRALGIA (shooting pain from shoulder down to hand) outcome was unknown and RASH (developed a rash on her left arm extending from arm to elbow and upto shoulder) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient used Ice for treatment medication. No Concomitant medication has been provided by reporter.
Sex: U
Vaccine: COVID19
Symptoms: Chills, Cough, Diarrhoea, Dyspnoea, Headache
Clinical narrative: After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again; shortness of breath; cough; Diarrhea; chills; Muscle ache; Headache; Fever; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea) and CHILLS (chills) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea), CHILLS (chills), MYALGIA (Muscle ache), HEADACHE (Headache) and PYREXIA (Fever). At the time of the report, SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea), CHILLS (chills), MYALGIA (Muscle ache), HEADACHE (Headache) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Sep-2021, SARS-CoV-2 test: positive (Positive) Type of test- Not rapid Sample- Nasal.         No concomitant medication information provided by the reporter. No treatment information provided. Patients was also having abdominal pain.   This case was linked to MOD-2021-315854 (Patient Link).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 14-Sep-2021: Significant Follow up received on 14 sep 2021 contains new events: fever, chills, shortness of breath, cough, muscle ache, headache, diarrhea.
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, SARS-CoV-2 test, Suspected COVID-19
Clinical narrative: After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again; shortness of breath; cough; Diarrhea; chills; Muscle ache; Headache; Fever; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea) and CHILLS (chills) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea), CHILLS (chills), MYALGIA (Muscle ache), HEADACHE (Headache) and PYREXIA (Fever). At the time of the report, SUSPECTED COVID-19 (After virus, we waited for no symptoms to get second vaccine. Are now miserable with symptoms exactly like we have virus again), DYSPNOEA (shortness of breath), COUGH (cough), DIARRHOEA (Diarrhea), CHILLS (chills), MYALGIA (Muscle ache), HEADACHE (Headache) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Sep-2021, SARS-CoV-2 test: positive (Positive) Type of test- Not rapid Sample- Nasal.         No concomitant medication information provided by the reporter. No treatment information provided. Patients was also having abdominal pain.   This case was linked to MOD-2021-315854 (Patient Link).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 14-Sep-2021: Significant Follow up received on 14 sep 2021 contains new events: fever, chills, shortness of breath, cough, muscle ache, headache, diarrhea.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dyspnoea, Fatigue, Feeling abnormal, Headache
Clinical narrative: Intermittent Tachycardia; Shortness of Breath; Chest discomfort; Slept for 12 hours straight/Unable to get out of bed; Became very fatigued; Had headache; This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath), CHEST DISCOMFORT (Chest discomfort), FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed) and FATIGUE (Became very fatigued) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 037K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to antibiotic (Amoxicillin) and Exercise induced asthma since February 2000. Concomitant products included CURCUMA LONGA (TURMERIC [CURCUMA LONGA]) and PROBIOTICS NOS for an unknown indication.   On 24-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Jan-2021, the patient experienced TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath), CHEST DISCOMFORT (Chest discomfort), FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed), FATIGUE (Became very fatigued) and HEADACHE (Had headache). At the time of the report, TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath) and FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed) had resolved and CHEST DISCOMFORT (Chest discomfort), FATIGUE (Became very fatigued) and HEADACHE (Had headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 145 (High) Heart rate elevated to 145 - 150 (When attempting to go upstairs).     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Lab investigations included: Troponin, Sedimentation rate, CBC, CMP and also Echocardiogram, Holter monitor- Where all the results were in their normal ranges  Other concomitant medications include: Mushroom immune booster which are taken orally  Treatment information was not reported   This case was linked to MOD-2021-010602 (Patient Link).
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate, Tachycardia
Clinical narrative: Intermittent Tachycardia; Shortness of Breath; Chest discomfort; Slept for 12 hours straight/Unable to get out of bed; Became very fatigued; Had headache; This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath), CHEST DISCOMFORT (Chest discomfort), FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed) and FATIGUE (Became very fatigued) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 037K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to antibiotic (Amoxicillin) and Exercise induced asthma since February 2000. Concomitant products included CURCUMA LONGA (TURMERIC [CURCUMA LONGA]) and PROBIOTICS NOS for an unknown indication.   On 24-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Jan-2021, the patient experienced TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath), CHEST DISCOMFORT (Chest discomfort), FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed), FATIGUE (Became very fatigued) and HEADACHE (Had headache). At the time of the report, TACHYCARDIA (Intermittent Tachycardia), DYSPNOEA (Shortness of Breath) and FEELING ABNORMAL (Slept for 12 hours straight/Unable to get out of bed) had resolved and CHEST DISCOMFORT (Chest discomfort), FATIGUE (Became very fatigued) and HEADACHE (Had headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 145 (High) Heart rate elevated to 145 - 150 (When attempting to go upstairs).     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Lab investigations included: Troponin, Sedimentation rate, CBC, CMP and also Echocardiogram, Holter monitor- Where all the results were in their normal ranges  Other concomitant medications include: Mushroom immune booster which are taken orally  Treatment information was not reported   This case was linked to MOD-2021-010602 (Patient Link).
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site pain, Vaccination site rash, Vaccination site swelling, Vaccination site warmth
Clinical narrative: hot to the touch; more than a rash, it was above the skin level like a plateau 3 inches; arm is really sore; feels very tired; rash/more than a rash, it was above the skin level like a plateau 3 inches for 5 inches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE SWELLING (more than a rash, it was above the skin level like a plateau 3 inches), VACCINATION SITE PAIN (arm is really sore), FATIGUE (feels very tired) and VACCINATION SITE RASH (rash/more than a rash, it was above the skin level like a plateau 3 inches for 5 inches) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Aug-2021, the patient experienced VACCINATION SITE RASH (rash/more than a rash, it was above the skin level like a plateau 3 inches for 5 inches). On an unknown date, the patient experienced VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE SWELLING (more than a rash, it was above the skin level like a plateau 3 inches), VACCINATION SITE PAIN (arm is really sore) and FATIGUE (feels very tired). The patient was treated with FISH OIL for Adverse event, at an unspecified dose and frequency and BIFIDOBACTERIUM LACTIS (PROBIOTIC [BIFIDOBACTERIUM LACTIS]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE SWELLING (more than a rash, it was above the skin level like a plateau 3 inches), VACCINATION SITE PAIN (arm is really sore) and FATIGUE (feels very tired) outcome was unknown and VACCINATION SITE RASH (rash/more than a rash, it was above the skin level like a plateau 3 inches for 5 inches) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medication of the patient was not reported.  The patient experienced the first symptoms one week after the first dose. The rash appeared exactly one week after the vaccine and lasted one week also. The patient described it as more than a rash, it was above the skin level like a plateau 3 inches for 5 inches. It was spread in an unusual manner and was rising up from the skin. The reporter said it was like a blob.   This case was linked to MOD-2021-317936 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 13-Sep-2021: Follow-up information included no new information.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Ejection fraction, Myocarditis, Troponin I
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 21-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 50% LVEF-50%. On an unknown date, Troponin I: 4.4ng/ml 4.4ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    Concomitant medications were not reported. Therapy for the event was not reported. It was reported that all patients recovered within 6 days of their presentation with complications. This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications.  This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS  in a 21-year-old female patient after receiving the second dose of mRNA-1273.  Based on the current available information and reporter´s causality  a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317976, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS  in a 21-year-old female patient after receiving the second dose of mRNA-1273.  Based on the current available information and reporter´s causality  a causal relationship cannot be excluded.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Ejection fraction, Myocarditis, Troponin I
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Ejection fraction: 54% (normal) 54%. In 2021, Troponin I: 6.77 ng/ml (High) 6.77 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    Concomitant Medications were not reported.  Therapy for event was not reported.  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis  in a 52-year-old male patient who received mRNA-1273. Based on the current available information and reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317976, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis  in a 52-year-old male patient who received mRNA-1273. Based on the current available information and reporter´s causality , a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Herpes zoster meningitis
Clinical narrative: severe case of shingles leading to spinal meningitis; shingles leading to spinal meningitis; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 13-Sep-2021 and was forwarded to Moderna on 13-Sep-2021.    This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER MENINGITIS (severe case of shingles leading to spinal meningitis) and HERPES ZOSTER (shingles leading to spinal meningitis) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On 03-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, the patient experienced HERPES ZOSTER MENINGITIS (severe case of shingles leading to spinal meningitis) (seriousness criteria hospitalization and medically significant) and HERPES ZOSTER (shingles leading to spinal meningitis) (seriousness criterion hospitalization). The patient was hospitalized on sometime in May 2021 due to HERPES ZOSTER and HERPES ZOSTER MENINGITIS. At the time of the report, HERPES ZOSTER MENINGITIS (severe case of shingles leading to spinal meningitis) and HERPES ZOSTER (shingles leading to spinal meningitis) outcome was unknown.            Patient was taking immunosuppressants but stopped since being Hospitalized.  No treatment information was provided.  This case concerns a female patient with no relevant medical history, who experienced the unexpected event of Herpes Zoster Meninigitis and Herpes zoster. The events occurred approximately 2 months after the second dose of Spikevax.  The events were considered related to the product per the reporter's assessment. The events are consistent with the current understanding of the mechanism of action of the vaccine. The benefit-risk relationship of Spikevax is not affected by this report.; Sender's Comments: This case concerns a female patient with no relevant medical history, who experienced the unexpected event of Herpes Zoster Meninigitis and Herpes zoster. The events occurred approximately 2 months after the second dose of Spikevax.  The events were considered related to the product per the reporter's assessment. The events are consistent with the current understanding of the mechanism of action of the vaccine. The benefit-risk relationship of Spikevax is not affected by this report.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Exposure to SARS-CoV-2
Clinical narrative: her Mother-In-Law became symptomatic; She exposed to Daughter-In-Law on Friday 10SEP2021; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (her Mother-In-Law became symptomatic), EXPOSURE TO SARS-COV-2 (She exposed to Daughter-In-Law on Friday 10SEP2021) and PRODUCT DOSE OMISSION ISSUE (trying to decide if she should receive the second dose today 13SEP2021) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Sep-2021, the patient experienced EXPOSURE TO SARS-COV-2 (She exposed to Daughter-In-Law on Friday 10SEP2021). On 13-Sep-2021, the patient experienced COVID-19 (her Mother-In-Law became symptomatic). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (trying to decide if she should receive the second dose today 13SEP2021). At the time of the report, COVID-19 (her Mother-In-Law became symptomatic), EXPOSURE TO SARS-COV-2 (She exposed to Daughter-In-Law on Friday 10SEP2021) and PRODUCT DOSE OMISSION ISSUE (trying to decide if she should receive the second dose today 13SEP2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications was not provided by the reporter Treatment information was not provided
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Product administered to patient of inappropriate age, Product dose omission issue
Clinical narrative: Greater than 35 days since first dose; Mild headache; Sore arm; Inadvertently administered dose to a teenager; This spontaneous case was reported by an other health care professional and describes the occurrence of HEADACHE (Mild headache), MYALGIA (Sore arm), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inadvertently administered dose to a teenager) and PRODUCT DOSE OMISSION ISSUE (Greater than 35 days since first dose) in a 13-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jul-2021, the patient experienced HEADACHE (Mild headache), MYALGIA (Sore arm) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inadvertently administered dose to a teenager). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Greater than 35 days since first dose). On 29-Jul-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inadvertently administered dose to a teenager) had resolved. On 30-Jul-2021, HEADACHE (Mild headache) and MYALGIA (Sore arm) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Greater than 35 days since first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information were provided. No treatment information were provided
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: reaction to the COVID-19 vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (reaction to the COVID-19 vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (reaction to the COVID-19 vaccine). At the time of the report, VACCINATION COMPLICATION (reaction to the COVID-19 vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter stated that her provider had a reaction to the COVID-19 vaccine. Reporter did not report the severity of the reaction.  Concomitant medications were not provided. Treatment information was not provided.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain, Body temperature, Diarrhoea, Off label use, Pyrexia
Clinical narrative: Not immunocompromised/gave booster dose; Vomiting after 3rd dose; Temperature 100.3F after 3rd dose; Abdominal pain  after 3rd dose; Diarrhea after 3rd dose; This spontaneous case was reported by a nurse and describes the occurrence of ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), OFF LABEL USE (Not immunocompromised/gave booster dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058F21A) for COVID-19 vaccination.     Concurrent medical conditions included Pancreatitis (Patient has Pancreatitis which has been under control for the past 3 years.) and Heart disorder.    On 07-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021, the patient experienced ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose). On an unknown date, the patient experienced OFF LABEL USE (Not immunocompromised/gave booster dose). At the time of the report, ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), OFF LABEL USE (Not immunocompromised/gave booster dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Sep-2021, Body temperature: 100.3 (High) 100.3 F.         No concomitant medications were provided by reporter.  No treatment medications were provided by reporter.  Patient received the first dose of Moderna COVID-19 vaccine on 04FEB2021 (Lot number: 031L20A and Exp. Date: 22JUL2021). He received the second dose of Moderna COVID-19 vaccine on 04MAR2021 (Lot number 013A21A and Exp. Date: 20AUG2021). On13 Sep 2021, He was able to hold down clear liquids. His medical history of Pancreatitis was under control for the past 3 years and he had a heart condition. Reporter stated that patient was not immunocompromised. However, took the booster dose. Later, found out that the 3rd slot was for immunocompromised people only.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Not immunocompromised/gave booster dose; Vomiting after 3rd dose; Temperature 100.3F after 3rd dose; Abdominal pain  after 3rd dose; Diarrhea after 3rd dose; This spontaneous case was reported by a nurse and describes the occurrence of ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), OFF LABEL USE (Not immunocompromised/gave booster dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058F21A) for COVID-19 vaccination.     Concurrent medical conditions included Pancreatitis (Patient has Pancreatitis which has been under control for the past 3 years.) and Heart disorder.    On 07-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021, the patient experienced ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose). On an unknown date, the patient experienced OFF LABEL USE (Not immunocompromised/gave booster dose). At the time of the report, ABDOMINAL PAIN (Abdominal pain  after 3rd dose), DIARRHOEA (Diarrhea after 3rd dose), OFF LABEL USE (Not immunocompromised/gave booster dose), VOMITING (Vomiting after 3rd dose) and PYREXIA (Temperature 100.3F after 3rd dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Sep-2021, Body temperature: 100.3 (High) 100.3 F.         No concomitant medications were provided by reporter.  No treatment medications were provided by reporter.  Patient received the first dose of Moderna COVID-19 vaccine on 04FEB2021 (Lot number: 031L20A and Exp. Date: 22JUL2021). He received the second dose of Moderna COVID-19 vaccine on 04MAR2021 (Lot number 013A21A and Exp. Date: 20AUG2021). On13 Sep 2021, He was able to hold down clear liquids. His medical history of Pancreatitis was under control for the past 3 years and he had a heart condition. Reporter stated that patient was not immunocompromised. However, took the booster dose. Later, found out that the 3rd slot was for immunocompromised people only.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: bad reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (bad reaction) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (bad reaction). At the time of the report, VACCINATION COMPLICATION (bad reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant drug information does not provided . Treatment information does not provided.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: sore injection site left arm/ left arm was sore for two days; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore injection site left arm/ left arm was sore for two days) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     The patient's past medical history included Stools watery (history of watery stools 20 years ago.).   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYALGIA (sore injection site left arm/ left arm was sore for two days). On 03-Apr-2021, MYALGIA (sore injection site left arm/ left arm was sore for two days) had resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information provided. No treatment information provided.   This case was linked to MOD-2021-319120 (Patient Link).
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Vomiting
Clinical narrative: Diarrhea; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea) and VOMITING (Vomiting) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis since 1994 and Sjogren's syndrome since 2005. Concomitant products included TOCILIZUMAB (ACTEMRA) in 2019, METHOTREXATE from 1998 to 15-Sep-2021 and HYDROXYCHLOROQUINE SULFATE (PLAQUENIL S) from 1994 to an unknown date for Rheumatoid arthritis, CICLOSPORIN (RESTASIS) from 2021 to an unknown date for Sjogren's disease, ATENOLOL from 2021 to an unknown date for Tachycardia.    On 09-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced DIARRHOEA (Diarrhea) and VOMITING (Vomiting). At the time of the report, DIARRHOEA (Diarrhea) and VOMITING (Vomiting) outcome was unknown.            No treatment medication was reported. Patient states that got Moderna vaccine booster dose 0n 09-sep-2021 and experienced vomiting and diarrhea.    This case was linked to MOD-2021-324289 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 21-Sep-2021: Follow up received, updated patient details, medical history and concomitant medications.
Age: 83.0
Sex: U
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: I experienced sever itching at different times on different parts of the body(Buttocks,back,shoulders,arms,palms); This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (I experienced sever itching at different times on different parts of the body(Buttocks,back,shoulders,arms,palms)) in an 83-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021, the patient experienced PRURITUS (I experienced sever itching at different times on different parts of the body(Buttocks,back,shoulders,arms,palms)). At the time of the report, PRURITUS (I experienced sever itching at different times on different parts of the body(Buttocks,back,shoulders,arms,palms)) outcome was unknown.            No concomitant medications were reported. No treatment medications were reported.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Such bad side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Such bad side effects) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Such bad side effects). At the time of the report, VACCINATION COMPLICATION (Such bad side effects) outcome was unknown.            No Concomitant product details were provided by the reporter. No Treatment information was provided.   Reporter did not allow further contact
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Bone pain, Chills, Erythema, Feeling hot, Flushing
Clinical narrative: Redness/erythema; Flushing; Feeling hot; Increased heart rate; severe bone pain; Chills; headache; malar rash on face; Nausea; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate) and BONE PAIN (severe bone pain) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to vaccine (welts down arm from injection site to wrist (almost in a distribution line) following vein/or nerve gone by day 3) since 2020, Dysautonomia (worsened, sores in nose, vertigo, increased pain in joints and bones, increased dryness, and dizziness) since 2020 and Sjogren's syndrome (worsened, sores in nose, vertigo, increased pain in joints and bones, increased dryness, and dizziness) in 2020. Concomitant products included HYDROXYCHLOROQUINE SULFATE (PLAQUENIL S), NALTREXONE HYDROCHLORIDE (NALTREXON), TOPIRAMATE, PANTOPRAZOLE and KETOTIFEN from an unknown date to 09-Apr-2021 for an unknown indication.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, the patient experienced ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate), BONE PAIN (severe bone pain), CHILLS (Chills), HEADACHE (headache), RASH (malar rash on face), NAUSEA (Nausea) and VOMITING (Vomiting). The patient was treated with PREDNISONE for Adverse event, at an unspecified dose and frequency; KETOROLAC TROMETHAMINE (TORADOL) for Adverse event, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) on 16-Aug-2021 for Adverse event, at an unspecified dose and frequency. On 22-Aug-2021, ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate), BONE PAIN (severe bone pain), CHILLS (Chills), HEADACHE (headache), RASH (malar rash on face), NAUSEA (Nausea) and VOMITING (Vomiting) had resolved.            Patient suffered from Sjogrens flare and vertigo. Date recovered: 22-AUG-2021
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Heart rate increased, Nausea, Rash, Vomiting
Clinical narrative: Redness/erythema; Flushing; Feeling hot; Increased heart rate; severe bone pain; Chills; headache; malar rash on face; Nausea; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate) and BONE PAIN (severe bone pain) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to vaccine (welts down arm from injection site to wrist (almost in a distribution line) following vein/or nerve gone by day 3) since 2020, Dysautonomia (worsened, sores in nose, vertigo, increased pain in joints and bones, increased dryness, and dizziness) since 2020 and Sjogren's syndrome (worsened, sores in nose, vertigo, increased pain in joints and bones, increased dryness, and dizziness) in 2020. Concomitant products included HYDROXYCHLOROQUINE SULFATE (PLAQUENIL S), NALTREXONE HYDROCHLORIDE (NALTREXON), TOPIRAMATE, PANTOPRAZOLE and KETOTIFEN from an unknown date to 09-Apr-2021 for an unknown indication.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, the patient experienced ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate), BONE PAIN (severe bone pain), CHILLS (Chills), HEADACHE (headache), RASH (malar rash on face), NAUSEA (Nausea) and VOMITING (Vomiting). The patient was treated with PREDNISONE for Adverse event, at an unspecified dose and frequency; KETOROLAC TROMETHAMINE (TORADOL) for Adverse event, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) on 16-Aug-2021 for Adverse event, at an unspecified dose and frequency. On 22-Aug-2021, ERYTHEMA (Redness/erythema), FLUSHING (Flushing), FEELING HOT (Feeling hot), HEART RATE INCREASED (Increased heart rate), BONE PAIN (severe bone pain), CHILLS (Chills), HEADACHE (headache), RASH (malar rash on face), NAUSEA (Nausea) and VOMITING (Vomiting) had resolved.            Patient suffered from Sjogrens flare and vertigo. Date recovered: 22-AUG-2021
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Asthenia, Cold sweat, Decreased appetite
Clinical narrative: lost taste; lost smell; no appetite; lost so much weight; had no energy; lethargic; had to push himself every day to go to work; felt like he had COVID 19; wasn't feeling well; woke up at night in cold sweat; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (wasn't feeling well), COLD SWEAT (woke up at night in cold sweat), AGEUSIA (lost taste), ANOSMIA (lost smell) and DECREASED APPETITE (no appetite) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 053E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 17-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Aug-2021, the patient experienced MALAISE (wasn't feeling well) and COLD SWEAT (woke up at night in cold sweat). On 18-Aug-2021, the patient experienced AGEUSIA (lost taste), ANOSMIA (lost smell), DECREASED APPETITE (no appetite), WEIGHT DECREASED (lost so much weight), ASTHENIA (had no energy), LETHARGY (lethargic), IMPAIRED WORK ABILITY (had to push himself every day to go to work) and FEELING ABNORMAL (felt like he had COVID 19). On 17-Aug-2021, MALAISE (wasn't feeling well) had resolved. On 18-Aug-2021, COLD SWEAT (woke up at night in cold sweat) had resolved. On 25-Aug-2021, AGEUSIA (lost taste), ANOSMIA (lost smell), DECREASED APPETITE (no appetite), WEIGHT DECREASED (lost so much weight), ASTHENIA (had no energy), LETHARGY (lethargic), IMPAIRED WORK ABILITY (had to push himself every day to go to work) and FEELING ABNORMAL (felt like he had COVID 19) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Aug-2021, SARS-CoV-2 antibody test: negative (Negative) test showed no Antibodies.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medications were provided  No treatment medications were provided.